Member Info for TWatcher

Mologic have also applied for FDA EUA in the the US and have had >$10M from the US Radx program.

That's concrete prove that Mologic are targeting rich countries as well as developing nations.

BigBangs, What ODX said was:-

We plan to submit the data from the study to our European Notified Body by the end of the month and we are working with them to explore how we can fast track approval. Once we receive approval we have high expectations that our distribution partners will be very successful in the market place with one of the first UK-developed and manufactured self-test products to enter the market.
We are also mindful that once we have self-test approval the VISITECT COVID-19 Antigen test would potentially be available for future DHSC purchase as a UK-developed and UK-made rapid point-of-care test for active COVID-19.

So submitting at end of month...looking at ways to fast track approval....then once approved potentially available to DHSC. To be fair, I am unsure of the exact process and how CE approval for self-test dials into Portdon Down evaluation to get to stage 3B level. My understanding is that 3B requires some insitu usage trials by staff/end users.

BigBangs, remembering that Surescreen have been producing a HMG test for months now. They received over £20M in May.

So What exactly is holding up ODX making HMG tests.

It's not ODX, they are clearly gagging to get making LFTs
It's not that there isn't a suitable test, ODX have said that HMG have put them in contact with test providers that have tests that have "been approved by the DHSC and also have self-test approval".
It's not that the tests are incompatible with ODX production techniques as ODX have said: "We have already concluded technical diligence with these parties and we are confident that the transfer time can be expedited"

So a couple of thoughts:-

1) Its not clear who is actually leading these discussions. ODX has said that HMG has "facilitated discussions" with potential suppliers. But who is striking the deal. Is it HMG is it ODX? Who is setting the royalty price ? Surely HMG would have more clout in getting the job done, than ODX, who everyone knows NEEDS a deal. Is ODX dealing just for themselves, is GAD also independently dealing ? Anyhow, whoever is dealing, it is possible that they (either ODX or HMG) can not agree terms with any of the suppliers to make their IP available to ODX. If the potential source of the test has a large capacity, then you can understand that they'd rather make and sell all of their capacity. But then they would not have gotten as far as ODX confirming they can make that test.

2) HMG isn't as pressed for uk sourced LFTs as their public face persona would have us believe.

What are the other potential reasons why things have not progressed ?

Our own branded one that is identical to the Mologic one has repeatedly failed PD testing. So that can not be selected by HMG, hence the "had hoped" statement. ODX indicated that it is they, not Mologic that are doing the sample handling changes, and so ODX will have to submit their test to PD to pass thru the various stages, and then it will be eligible for selection. But IMO the quickest way to HMG output is that HMG select some test NOW and odx can get on with TTing.

Tonic, that is indeed the more hopeful section of the statement, and I pointed that out at the time. However, it does require the test to complete internal validation, and then be submitted by ODX (not Mologic) to go thru the various phases 1,2,3 etc of the validation process, to get Porton Down to sign off on it.

That looks a ways down the line IMO, and was only held out as a possibility, "potentially be available"

The original poster was suggesting that the Mologic test might be selected, an I advised him of the appropriate section of the statement in the full official RNS results.

If you don't like that the CEO's hope for Mologic being selected was in the past tense, you need to take it up with him.

If you don't like facts, then you have another problem.

The possibility of the Mologic test being selected is dead in the water given the phrasing used in the full year results:-

"We had hoped that the Mologic test would be chosen by the DHSC as a UK-developed test to be made by us as UK manufacturers, however the contract itself is test agnostic and we are prepared to manufacture whichever test is chosen."

WE HAD HOPED...past tense.

They were unavailable for about an hr.

Ask tricky, she was the one remarking that the "whole market" was down today. Testing seems to be bucking the trend.

"I see no competition
Mologic is ( and was always) aiming to help the 3rd world poor countries. Now they have even more money to do so. good."

Mologic has applied for FDA approval in the US, the richest country in the world.

"I see no competition
Mologic is ( and was always) aiming to help the 3rd world poor countries. Now they have even more money to do so. good.
ODX is aiming for rich countries US/UK/EU."

Mologic has applied for FDA approval in the US, the richest country in the world.

DM83,

I, and I assume many others got into ODX as a covid play. They do appear to have a great product in food detective, and also the CD4 tests, but I'd never heard of them and it's not why I'm here.

The short answer is that it is all about orders. ODX historically have not had any. And they have been promising them since Oct last year, using not dissimilar rhetoric to what we hear today. Oct 2020 presentation said that antibody testing would occur as part of the vaccine roll, now its suggested it'll happen shortly (the word imminent was used ?), possibly as part of a booster campaign.
Antigen sales were expected by many in Feb, and then the company said an unconditional 2M per week delivery of LFTs in April, which was obvious for a long time that that didn't happen, and they confirmed it in the presentation.

They also spent many months (more than was expected) TTing a test which is now known to have repeatedly failed Porton Down testing, a mandatory requirement for it to be used by uk Gov. How that impacts the saleability of their generic visitect variant was not mentioned, but it clearly has an impact. It is not surprisingly therefore that they are trying to differientiate it. Also CE approval was targeted for end of this month, but now it appears this is pushed out further.

So for me the company has a credibility issue, they have spent time making tests that no one wants (vistiect tri-antibody test, the elisa test), and have misread the market and have repeatedly seriously misjudged timings. They have also left their fortunes in the hands of others. The government regarding antibody / antigen contracts, Abingdon as lead of the RTC is soley responsible for getting those sales, and it is Mologic that has been submitting and dealing with Porton Down for the antigen testing and indeed dealing with the FDA for EUA.

Nothing short of firm orders will resolve that. If they can get to announce a good firm definite order, and indeed announce production, then the SP will quickly respond, and if they can show good visibility to fully utilise the capacity then we'll all be in a far better place.

However, ODX seems to have stalled into the "potential" category for far far too long, at that is still where we find ourselves 15 months into the pandemic.

Soros and Gates et al liked the ethos of a Mologic, a private company that had ethical responsibility high on their agenda, to the extent that they have now bought up the company and intend to operate at close as possible as a not of profit operation. It was relatively easy to purchase as it was held in private hands.

ODX is a listed company with shareholders and many directors with share options, who (although notionally at this stage) want to maximise profit, as any listed company should do.

People would be better if they stopped all this highly tangential speculation day after day based on any little bit of news. This weekend we've had Mologic being bought out and turning non-profit, and we had the momentary repositioning of Mr Deeks from a dark knight to a guardian Angel on the basis of one teasing tweet, that ended up being nothing but referencing the Mologic deal. Many don't seem to see that Mologc effectively turning into a not-for-profit is goin to be selling the mologic test really cheaply. Its' going to be difficult for ODX to make good profit on their generic equivalent, never mind the fact they also have to pay Mologic a royalty.

And then we have self-professed experts, who are clearly badly misinformed and can't compehend an RNS when they extend work that ODX is doing to enhance the visitect Mologic test, and assume that this means that the Mologic original will now suddenly be compliant with selftesting ???

Heres an actual question. Given ODX are now making a derivative of the original Mologic test, which changes the handling, are ODX going to run with two visitect tests going forward.

If/when the Mologic original starts getting orders on the back of ce approval and the germany test, or indeed the Radx/USA FDA submission which has been confirmed to also apply to the ODX generic variant, one assumes ODX will have to supply the exact generic visitect variant, as any approval will only apply to that exact test. They will also then run with the enhanced useability variant, get apply for approval etc for that separately ?

Refer to the same contract, the more recent one includes a link to the redacted contract.

Had to come off it, the rules were that people would be choosen at random.

oh matron !

actually 3 companies are listed there, Innova(£144M), Tanner Pharma (£104M), and Medco solutions (£62.5M), all with a delivery window from June to Dec 2021.

Looking at all three contracts, they all have a large area of the description of the goods blanked out. At the end of each have a small descriptive piece on the company.

The piece on Innova talks about their factory in wales and says that "they expect to start producing product in June 2021", and that they are looking for an additional factory to start production at the beginning of 2022.

https://atamis-1928.cloudforce.com/sfc/p/#0O000000rwim/a/4J000000QBz9/kgEhGyUxekk5mE0qYYShDabZPxBopXSYHj0KQf.NJGQ

see page 39

As soon as I see anything from you that warrants being described as a contribution, I'll let you know.

One of the many that resorts to insults and diatribe when the argument is lost.